New company Arvelle Therapeutics secures EU rights to cenobamate for treatment of focal( partial offset) seizures.- Arvelle + SK Biopharmaceuticals

Axovant Sciences , a clinical-stage company developing innovative gene therapies, announces the formation of Arvelle Therapeutics and the strategic transition of its legacy small molecule team into the newly-formed company. Arvelle has licensed European rights to cenobamate, a novel investigational anti-epileptic drug for the potential treatment of focal (partial-onset) seizures, from SK Biopharmaceuticals.

Axovant will receive a 5% preferred equity stake in Arvelle following the completion of the planned initial capital raise of over $100 million from a global syndicate of biotechnology investors. SK Biopharmaceuticals filed a new drug application (NDA) with the FDA in November 2018 and this filing was accepted by the agency in February 2019, with a PDUFA date of 21 November 2019. Arvelle plans to file a Marketing Authorization Application (MAA) based on the data generated from SK Biopharmaceutical�s global clinical trial program.